Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1099-1111

  Hu, Yong Xian ^a   Cui, Qu ^b,c   Liang, Bin ^d   Huang, He ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JILIN UNIVERSITY   (China)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Graft versus tumor; Human leukocyte antigen compatibility; Targeted therapy

Indexed keywords

ALEMTUZUMAB; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MELPHALAN; METHOTREXATE; OKT 3; SEMUSTINE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CORRELATIONAL STUDY; CYTOTOXICITY; EPIGENETICS; FEASIBILITY STUDY; FOLLOW UP; GENETIC VARIABILITY; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; ORGAN DONOR; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; REVIEW; SOLID TUMOR; TREATMENT WITHDRAWAL; WHOLE BODY RADIATION;

ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80955180168     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.02.013     Document Type: Review

References (96)

1. Park J.A., Ghim T.T., Bae K., et al. Stem cell transplant in the treatment of childhood biphenotypic acute leukemia. Pediatr Blood Cancer 2009, 53:444-452.
2. Claviez A., Canals C., Dierickx D., et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin's lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:2060-2067.
3. Li C.K., Lee V., Shing M.M., et al. Hematopoietic stem cell transplantation for thalassaemia in Chinese patients. Hong Kong Med J 2009, 15:39-41.
4. Fuchs E.J., Huang X.J., Miller J.S. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:S57-S63.
5. Friedrich W., Goldmann S.F., Vetter U., et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T cell depleted bone marrow. Lancet 1984, 1:761-764.
6. Handgretinger R., Lang P. The history and future prospective of haploidentical stem cell transplantation. Cytotherapy 2008, 10:443-451.
7. Chen X.H., Gao L., Zhang X., et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cells Mol Dis 2009, 43:98-104.
8. Schwarer AP, Bollard G, Kapuscinski M, et al. Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical hematopoietic SCT. Bone Marrow Transplant. doi:10.1038/bmt.2010.299.
9. Chen Y., Liu K., Xu L., et al. HLA-mismatched hematopoietic SCT without in vitro T cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 2010, 45:1333-1339.
10. Dellabona P, Casorati G, de Lalla C, et al. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clin Immunol. doi:10.1016/j.clim.2010.11.015.
11. Huang X.J., Chang Y.J. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplan 2011, 17:197-204.
12. Kurokawa T., Ishiyama K., Ozaki J., et al. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol 2010, 91:661-669.
13. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
14. Symons H.J., Leffell M.S., Rossiter N.D., et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010, 16:533-542.
15. Xu L.P., Liu K.Y., Liu D.H., et al. The inferiority of G-PB to rhG-CSF mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010, 45:985-992.
16. Wang H.X., Yan H.M., Liu J., et al. Haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leuk Lymphoma 2009, 50:1488-1493.
17. Wang H.Y., Yan H.M., Duan L.N., et al. Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF mobilized marrow grafts without T-cell depletion: a single-center report of 45 cases. Pediatr Hematol Oncol 2009, 26:119-128.
18. Guo M., Sun Z., Sun Q.Y., et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009, 15:930-937.
19. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biol Blood Marrow Transplant 2009, 15:91-94.
20. Chen X.H., Zhang C., Zhang X., et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:266-273.
21. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
22. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
23. Liu D.H., Huang X.J., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008, 14:469-477.
24. Hiroyasu O., Kazuhiro I., Katsuji K., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008, 36:1-8.
25. Huang X.J., Xu L.P., Liu K.Y., et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008, 40:444-455.
26. Takao Y., Keiko O., Michihiro K., et al. Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematol 2007, 85:246-255.
27. Dong L.J., Wu T., Zhang M.J., et al. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007, 13:1515-1524.
28. Lu D.P., Dong L.J., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
29. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
30. Klingebiel T., Cornish J., Labopin M., et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size. An analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010, 115:3437-3446.
31. Ciurea S.O., Saliba R., Rondon G., et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT transplantation from family donors in children and adolescents. Bone Marrow Transplant 2010, 45:429-436.
32. Federmann B., Hagele M., Pfeiffer M., et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reducedintensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011, 25:121-129.
33. Stern M., Ruggeri L., Mancusi A., et al. Survival after T cell depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.
34. Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
35. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
36. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007, 25:690-697.
37. Marks D.I., Khattry N., Cummins M., et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006, 134:196-201.
38. Cairo M.S., Jordan C.T., Maley C.C., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. Report from the Committee on the Biological Considerations of Hematological Relapse Following Allogeneic Stem Cell Transplantation Unrelated to Graft-Versus-Tumor Effects: state of the science. Biol Blood Marrow Transplant 2010, 16:709-728.
39. Katzir H., Yeheskely-Hayon D., Regev R., et al. Role of the plasma membrane leaflets in drug uptake and multidrug resistance. FEBS J 2010, 277:1234-1244.
40. Michelle J.H., Seoyeon C., Alex H.B., et al. Mechanism of relapse in pediatric acute lymphoblastic leukemia. Cell Cycle 2008, 7:1315-1320.
41. Bram E.E., Stark M., Raz S., et al. Chemotherapeutic drug induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 2009, 11:1359-1370.
42. van Rood J.J., Eernisse J.G., van Leeuwen A. Leucocyte antibodies in sera from pregnant women. Nature 1958, 181:1735-1736.
43. Van Kampen C.A., Versteeg-van der Voort Maarschalk M.F., Langerak-Langerak J., et al. Pregnancy can induce long-persisting primed CTLs specific for inherited paternal HLA antigens. Hum Immunol 2001, 62:201-207.
44. Verdijk R.M., Kloosterman A., Pool J., et al. Pregnancy induces minor histocompatibility antigen specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004, 103:1961-1964.
45. Shaw B.E., Mayor N.P., Russell N.H., et al. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia 2010, 24:58-65.
46. Shaw B.E., Gooley T.A., Malkki M., et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007, 110:4560-4566.
47. Shaw B.E., Marsh S.G., Mayor N.P., et al. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006, 107:1220-1226.
48. Kawase T., Matsuo K., Kashiwase K., et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009, 113:2851-2858.
49. Dankers M.K., Roelen D.L., Korfage N., et al. Differential immunogenicity of paternal HLA class I antigens in pregnant women. Hum Immunol 2003, 64:600-606.
50. Moretta A., Pende D., Locatelli F., et al. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol 2009, 157:325-331.
51. Locatelli F., Pende D., Maccario R., et al. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009, 133:171-178.
52. Ruggeri L., Mancusi A., Burchielli E., et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008, 40:84-90.
53. Ruggeri L., Mancusi A., Burchielli E., et al. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006, 16:404-411.
54. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
55. Leung W., Iyengar R., Triplett B., et al. Comparison of killer Ig like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174:6540-6545.
56. Moretta L., Locatelli F., Pende D., et al. Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias. Tissue Antigens 2009, 75:103-109.
57. Rizzieri D.A., Storms R., Chen D.F., et al. Natural killer cell enriched donor lymphocyte infusions from a 3-6/6 HLA matched family member following non-myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1107-1114.
58. Wu C.J., Yang X.F., McLaughlin S., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000, 106:705-714.
59. Aversa F., Martelli M.F. Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Springer Semin Immunopathol 2004, 26:155-168.
60. Kodera Y., Nishida T., Ichinohe T., et al. Human leukocyte antigen haploidentical hematopoietic stem cell transplantation: indications and tentative outcomes in Japan. Semin Hematol 2005, 42:112-118.
61. Kanda J., Chao N.J., Rizzieri D.A. Haploidentical transplantation for leukemia. Curr Oncol Rep 2010, 12:292-301.
62. Xu L.P., Luo X.H., Chang Y.J., et al. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Ann Hematol 2009, 88:1015-1024.
63. Luo X.H., Chang Y.J., Xu L.P., et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009, 43:29-36.
64. Fondi C., Nozzoli C., Benemei S., et al. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant 2009, 15:938-947.
65. Dander E., Balduzzi A., Zappa G., et al. Interleukin-17 producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009, 88:1261-1272.
66. Vela-Ojeda J., Montiel-Cervantes L., Granados-Lara P., et al. Role of CD4+CD25+high Foxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. Stem Cells Dev 2010, 19:333-340.
67. Willemze1 A.J., Press R.R., Lankester A.C., et al. CsA exposure is associated with acute GVHD and relapse in children after SCT. Bone Marrow Transplant 2010, 45:1056-1061.
68. Liu Q.F., Fan Z.P., Zhang Y., et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009, 15:1376-1385.
69. Boatsman E.E., Fu C.H., Song S.C., et al. Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2010, 32:e57-e60.
70. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions. The long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
71. Garrido F., Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001, 83:117-158.
72. Seliger B., Maeurer M.J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000, 21:455-464.
73. Restifo N.P., Marincola F.M., Kawakami Y., et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996, 88:100-108.
74. Vago L., Perna S.K., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
75. Villalobos I.B., Takahashi Y., Akatsuka Y., et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 2010, 115:3158-3161.
76. Elmaagacli A.H., Beelen D.W., Trenn G., et al. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:771-777.
77. Kako S., Izutsu K., Oshima K., et al. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:937-939.
78. Dazzi F., Fozza C. Disease relapse after hematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007, 20:311-327.
79. Yegin Z.A., Ozkurt Z.N., Aki S.Z., et al. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transfus Apher Sci 2010, 42:239-245.
80. Griffioen M., van Egmond H.M., Barnby-Porritt H., et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica 2008, 93:1535-1543.
81. Burt R.K., Drobyski W.R., Seregina T., et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 2003, 31:903-910.
82. Abrahamsen I.W., Stronen E., Walchli S., et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 2010, 24:1901-1909.
83. Barker J.N., Doubrovina E., Sauter C., et al. Successful treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoma after cord blood transplant using third-party EBV-specific cytotoxic T-lymphocytes. Blood 2010, 116:5045-5049.
84. Baba T., Sato-Matsushita M., Kanamoto A., et al. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med 2010, 8:84.
85. Ruggeri L., Mancusi A., Burchielli E., et al. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007, 19:142-147.
86. Meraviglia S., Eberl M., Vermijlen D., et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010, 161:290-297.
87. D'Asaro M., La Mendola C., Di Liberto D., et al. Vγ9Vδ2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010, 184:3260-3268.
88. Barkholt L., Alici E., Conrad R., et al. Safety analysis of ex vivo expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753-764.
89. Bashey A., Medina B., Corringham S., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1581-1588.
90. Kindler T., Lipka D.B., Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010, 116:5089-5102.
91. Gupta P., Goldenberg D.M., Rossi E.A., et al. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010, 116:3258-3267.
92. Dubovsky J.A., Wang D., Powers J.J., et al. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res 2011, 35:394-404.
93. Tuncer H.H., Gregory S.A., Fung H.C. High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma: a case report. Bone Marrow Transplant 2010, 10.1038/bmt.2010.251.
94. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
95. Kurosawa S., Fukuda T., Tajima K., et al. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation. Am J Hematol 2009, 84:815-820.
96. Wiedemann B., Klyuchnikov E., Kroger N., et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia (AML). Exp Hematol 2010, 38:1261-1271.